CDC EID journal |
SARS-CoV-2 Cluster in Nursery, Poland |
We report a cluster of surprisingly high spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) associated with a single nursery in Poland. Our findings contrast with the presumed negligible role of children in driving the SARS-CoV-2 pandemic. Children 1–2 years of age might be effective SARS-CoV-2 spreaders. |
|
---|---|---|---|
COVID-NMA |
https://covid-nma.com/ |
Cochrane FranceUniversité de ParisInsermAPHP |
Living mapping of researchLiving network meta-analysisAnalyse recherche thérapeutique et méta-analyse en temps-réelA suivre +++ |
Dashboard JHUDashboard WHO |
John hopkinsWHO |
Mapping des Cas/décès pays par pays |
Courbes d’incidence pays par paysLimites : pas de données sur le nombre de tests réalisés |
HAS |
Avis HAS du 08/10/2020 « COVID-19 : la HAS positionne les tests antigéniques dans trois situations », communiqué de presse du 09/10/2020https://www.has-sante.fr/upload/docs/application/pdf/2020-10/avis_n_2020.0059acseap_du_8_octobre_2020_du_college_de_la_haute_autorite_de_sante_relatif_a_lutilisation_de_la_detection_ant.pdf |
La Haute Autorité de santé a rendu fin septembre un avis favorable à l’utilisation des tests antigéniques sur prélèvement nasopharyngé chez les personnes qui présentent des symptômes de la COVID-19 : fièvre, toux sèche, perte de l’odorat ou du goût, etc. Elle en a précisé les performances requises : une sensibilité minimale supérieure à 80% et une spécificité minimale supérieure à 99%. Dans le même temps, la circulation du virus s’est accélérée et il est essentiel d’offrir à chacun une prise en charge optimale et de casser les chaînes de contamination pour endiguer l’épidémie. Pour y parvenir, il est nécessaire de prendre en compte d’autres paramètres que la sensibilité et la spécificité des tests, qui sont des prérequis. Il faut d’une part tester le plus grand nombre de personnes possible pour trouver plus de malades et d’autre part disposer de résultats le plus rapidement possible pour mettre en place les mesures d’isolement, tracer les personnes contacts et ainsi casser les chaines de contamination. C’est ce qui conduit la HAS à définir la stratégie d’utilisation des tests antigéniques dans la détection du virus. Ceux qui satisfont les critères de la HAS sont un peu moins sensibles que les tests RT-PCR, mais sont quasiment aussi spécifiques, permettent d’obtenir un résultat en moins de 30 minutes, et sont réalisables en dehors des seuls laboratoires d’analyses de biologie médicale. Aujourd’hui en France, le test RT-PCR sur prélèvement nasopharyngé reste le test de référence dans la détection du virus SARS-CoV-2. Mais la situation épidémique et les bonnes performances des tests antigéniques conduisent la HAS à positionner les différents tests pour trois situations cliniques : les patients symptomatiques, les personnes asymptomatiques contacts détectées isolément ou au sein de clusters et les personnes asymptomatiques qui vont être intégrées à un dépistage à grande échelle de populations ciblées. En revanche, la HAS considère qu’il n’y a pas lieu aujourd’hui de réaliser de dépistage non ciblé en population générale, compte tenu de l’absence de bénéfice de ce dépistage et de son probable rendement très faible. |
|
I3M/INSERM |
Revue Inserm |
Revue de littérature par I3M Institute |
– Revue de littérature de qualité des papiers acceptés pertinents selon l’équipe I3M |
Institut Pasteur |
https://www.pasteur.fr/fr/sars-cov-2-covid-19-institut-pasteur |
Institut Pasteur, Paris |
Ressources bibliographiques sur le SARS-CoV-2 et COVID-19 – Site de l’Institut Pasteur, Paris |
JAMA NETWORK |
Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-exposure SARS-CoV-2 Prophylaxis Among Health Care Workers: A Randomized Clinical Trial (30/09/2020) |
international, peer-reviewed, open access, general medical journal that publishes research and commentary on clinical care, health policy, and global health across all health disciplines and countries for clinicians, investigators |
In this double-blind, placebo-controlled randomized clinical trial that included 132 participants and was terminated early, there was not a significant difference in reverse-transcriptase polymerase chain reaction–confirmed SARS-CoV-2 incidence between hydroxychloroquine and placebo cohorts |
LitCovid |
NCBI/COVID |
Site du NCBI sur littérature scientifique COVID |
Accès à toutes les dernières publications par pays/date/domaine (mécanism, treatment, epidemic forectasting)→ Pratique et complet +++ |
Mbio |
Rescue of SARS-CoV-2 from a Single Bacterial Artificial Chromosome |
ASM JOURNAL |
This is, to our knowledge, the first BAC-based reverse genetics system for the generation of infectious rSARS-CoV-2 that displays features in vivo similar to those of a natural viral isolate. This SARS-CoV-2 BAC-based reverse genetics will facilitate studies addressing several important questions in the biology of SARS-CoV-2, as well as the identification of antivirals and development of vaccines for the treatment of SARS-CoV-2 infection and associated COVID-19 disease. |
Mbio |
SARS-CoV-2 Seroprevalence among a Southern U.S. Population Indicates Limited Asymptomatic Spread under Physical Distancing Measures |
ASM JOURNAL |
Characterizing the asymptomatic spread of SARS-CoV-2 is important for understanding the COVID-19 pandemic. This study was aimed at determining asymptomatic spread of SARS-CoV-2 in a suburban, Southern U.S. population during a period of state restrictions and physical distancing mandates. |
Ministère des Solidarités et de la Santé |
En mai 2020, 4,5 % de la population vivant en France métropolitaine a développé des anticorps contre le SARS-CoV-2 (0ç/10/2020) |
L’enquête EpiCoV a été élaborée par l’Institut national de la santé et de la recherche médicale (Inserm) et la DREES, en collaboration avec Santé publique France et l’Institut national de la statistique et des études économiques (Insee) dans le contexte de la pandémie de Covid-19. Cette enquête, réalisée auprès d’un échantillon représentatif de la population, est la seule qui permet d’estimer la diffusion de l’épidémie à un niveau national et départemental et les facteurs notamment liés aux conditions de vie associés à l’exposition au virus. Elle permet également d’étudier les répercussions du confinement et de l’épidémie sur la population. D’après cette enquête, la séroprévalence du SARS-CoV-2, c’est-à-dire la proportion de personnes avec des anticorps contre le virus, estimée à partir de prélèvements réalisés au décours du confinement, en mai 2020, s’élève à 4,5 % en France métropolitaine parmi les personnes âgées de 15 ans ou plus. La séroprévalence est la plus élevée à Paris (9,0 %), dans les départements de la petite couronne (9,5 %) et le Haut-Rhin (10,8 %). |
|
National Institute of Health |
NIH |
US department of health & human service |
Toute la recherche sur le COVID:– National Library of Medicine (COVID et Pubmed, clinical trials, explication du COVID-19 Open Research Dataset (CORD-19))– NIH Fogarty International Center : liens vers toutes les ressources biblio (Elsevier, Lancet, BMJ, Wiley, Mappings, NEJM)+ sélection articles en continu à COMPLET +++ |
National Institute of Health |
NIH COVID-19 Treatment Guidelines |
US department of health & human service |
A number of investigational agents and drugs that are approved for other indications are currently being studied in clinical trials for the treatment of COVID-19 and associated complications. |
National Institute of Health |
Therapeutic Management of Patients with COVID-19 NIH COVID-19 treatment guidelines |
US department of health & human service |
|
National Institute of Health – Pubmed |
Nouchi A, Chastang J, Miyara M, Lejeune J, Soares A, Ibanez G, Saadoun D, Morélot-Panzini C, Similowski T, Amoura Z, Boddaert J, Caumes E, Bleibtreu A, Lorenzo A, Tubach F, Pourcher V. Prevalence of hyposmia and hypogeusia in 390 COVID-19 hospitalized pat |
US department of health & human service |
We performed a cross-sectional survey during 5 consecutive days in March 2020, within a tertiary referral center, associated outpatient clinic, and two primary care outpatient facilities in Paris. All SARS-CoV-2-positive patients hospitalized during the study period and able to be interviewed (n = 198), hospital outpatients seen during the previous month (n = 129), and all COVID-19-highly suspect patients in two primary health centers (n = 63) were included. Hospitalized patients were significantly more often male (64 vs 40%) and older (66 vs 43 years old in median) and had significantly more comorbidities than outpatients. Hyposmia and hypogeusia were reported by 33% of patients and occurred significantly less frequently in hospitalized patients (12% and 13%, respectively) than in the health centers’ outpatients (33% and 43%, respectively) and in the hospital outpatients (65% and 60%, respectively). Hyposmia and hypogeusia appeared more frequently after other COVID-19 symptoms. Patients with hyposmia and/or hypogeusia were significantly younger and had significantly less respiratory severity criteria than patients without these symptoms. Olfactory and gustatory dysfunction occurs frequently in COVID-19, especially in young, non-severe patients. These symptoms might be a useful tool for initial diagnostic work-up in patients with suspected COVID-19. |
National Institute of Health – Pubmed |
Vangelista L, Secchi M. Prepare for the Future: Dissecting the Spike to Seek Broadly Neutralizing Antibodies and Universal Vaccine for Pandemic Coronaviruses. Front Mol Biosci. 2020 Sep 1;7:226. doi: 10.3389/fmolb.2020.00226. PMID: 33033717; PMCID: PMC749 |
US department of health & human service |
Learning from the lengthy fight against HIV-1, influenza, and Ebola virus infection, broadly neutralizing antibodies (bnAbs), directed at conserved regions of surface proteins crucial to virus entry (Env, hemagglutinin, and GP, respectively), are an essential resource for passive as well as active immunization. Rare in their emergence and antigen recognition mode, bnAbs are active toward a large set of different viral strains. Isolation, characterization and production of bnAbs lead to their possible use in passive immunotherapy and form the basis for an educated effort in the development of vaccines for universal coverage. SARS-CoV-2-specific antibodies targeting the spike receptor binding domain (RBD) may lead to antibody dependent enhancement (ADE) of infection, possibly hampering the field of vaccine development. This perspective points to the identification of conserved regions in the spike of SARS-CoV-2, SARS-CoV, and MERS-CoV through investigation, dissection and recombinant production of isolated moieties. These spike moieties should be capable of independent folding and allow the detection as well as the elicitation of bnAbs, thus setting the basis for an effective passive immunotherapy and the development of a universal vaccine against human epidemic coronaviruses (HCoVs). SARS, MERS and, most of all, COVID-19 demonstrate that humanity is the target of HCoV, preparedness for future hits is thus no longer an option. |
NATURE |
The major genetic risk factor for severe COVID-19 is inherited from Neanderthals |
International weekly journal of science |
A recent genetic association study1 identified a gene cluster on chromosome 3 as a risk locus for respiratory failure upon SARS-CoV-2 infection. A new study2 comprising 3,199 hospitalized COVID-19 patients and controls finds that this is the major genetic risk factor for severe SARS-CoV-2 infection and hospitalization (COVID-19 Host Genetics Initiative). Here, we show that the risk is conferred by a genomic segment of ~50 kb that is inherited from Neanderthals and is carried by ~50% of people in South Asia and ~16% of people in Europe today. |
NATURE |
Characteristics of SARS-CoV-2 and COVID-19 (06 October 2020) |
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a highly transmissible and pathogenic coronavirus that emerged in late 2019 and has caused a pandemic of acute respiratory disease, named ‘coronavirus disease 2019’ (COVID-19), which threatens human health and public safety. In this Review, we describe the basic virology of SARS-CoV-2, including genomic characteristics and receptor use, highlighting its key difference from previously known coronaviruses. We summarize current knowledge of clinical, epidemiological and pathological features of COVID-19, as well as recent progress in animal models and antiviral treatment approaches for SARS-CoV-2 infection. We also discuss the potential wildlife hosts and zoonotic origin of this emerging virus in detail. |
|
NEJM |
Rethinking Covid-19 Test Sensitivity — A Strategy for Containment (30/09/2020) |
The New England Journal of Medecine |
It’s time to change how we think about the sensitivity of testing for Covid-19. The Food and Drug Administration (FDA) and the scientific community are currently almost exclusively focused on test sensitivity, a measure of how well an individual assay can detect viral protein or RNA molecules. […] To defeat Covid-19, we believe that the FDA, the CDC, the National Institutes of Health, and others must encourage structured evaluations of tests in the context of planned testing regimens to identify those that will provide the best Covid filters. Frequent use of cheap, simple, rapid tests will accomplish that aim, even if their analytic sensitivities are vastly inferior to those of benchmark tests.1 Such a regimen can help us stop Covid in its tracks. |
NEJM |
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults (September 29, 2020) |
In this small study involving older adults, adverse events associated with the mRNA-1273 vaccine were mainly mild or moderate. The 100-μg dose induced higher binding- and neutralizing-antibody titers than the 25-μg dose, which supports the use of the 100-μg dose in a phase 3 vaccine trial. (Funded by the National Institute of Allergy and Infectious Diseases and others; mRNA-1273 Study ClinicalTrials.gov number, NCT04283461. opens in new tab.) |
|
Nextstrain |
https://nextstrain.org/ncov/global |
Real-time tracking of pathogen evolution |
Suivi évolution génome viral SARS-CoV-2 |
NY Times |
The coronavirus unveiled |
Quelques images |
|
OMS |
Questions-réponses sur les masques et les enfants dans le contexte de la COVID-19 (source OMS) |
||
REACTing |
https://reacting.inserm.fr/literature-review/ |
REACTing : coordinating French research response |
Partage toutes les semaines une sélection d’articles pertinents publiés sur le COVID-19 |
Santé Publique France |
SantéPublique France |
Agence Nationale de Santé Publique |
– Veille documentaire assez complète tout en bas à droite de la page (défaut : il faut retélécharger tous les pdf à chaque fois à bien ouvrir celui du jour)– Lien vers l’observatoire cartographique: GEODES à suivi indicateurs (hospi, réa, décès,par région, classe d’age, …), intéressant +++ |
Science Mag |
https://science.sciencemag.org/content/370/6512/22.full |
Revue scientifique américaine par l’Association américaine pour l’avancement des sciences (AAAS) |
A call for diagnostic tests to report viral load“Advocates point to new research indicating that CT values could help doctors flag patients at high risk for serious disease. Recent findings also suggest the numbers could help officials determine who is infectious and should therefore be isolated and have their contacts tracked down. CT value is an imperfect measure, advocates concede. But whether to add it to test results “is one of the most pressing questions out there,” says Michael Mina, a physician and epidemiologist at Harvard University’s T.H. Chan School of Public Health.” |
Science Mag |
https://science.sciencemag.org/content/370/6513/203.full |
Revue scientifique américaine par l’Association américaine pour l’avancement des sciences (AAAS) |
In situ structural analysis of SARS-CoV-2 spike reveals flexibility mediated by three hinges“The spike protein (S) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is required for cell entry and is the primary focus for vaccine development. In this study, we combined cryo–electron tomography, subtomogram averaging, and molecular dynamics simulations to structurally analyze S in situ. Compared with the recombinant S, the viral S was more heavily glycosylated and occurred mostly in the closed prefusion conformation. We show that the stalk domain of S contains three hinges, giving the head unexpected orientational freedom. We propose that the hinges allow S to scan the host cell surface, shielded from antibodies by an extensive glycan coat. The structure of native S contributes to our understanding of SARS-CoV-2 infection and potentially to the development of safe vaccines.” |
Science Mag |
Inborn errors of type I IFN immunity in patients with life-threatening COVID-19 (Science 24 Sep 2020) |
Revue scientifique américaine par l’Association américaine pour l’avancement des sciences (AAAS) |
Clinical outcome upon infection with SARS-CoV-2 ranges from silent infection to lethal COVID-19. We have found an enrichment in rare variants predicted to be loss-of-function (LOF) at the 13 human loci known to govern TLR3- and IRF7-dependent type I interferon (IFN) immunity to influenza virus, in 659 patients with life-threatening COVID-19 pneumonia, relative to 534 subjects with asymptomatic or benign infection. By testing these and other rare variants at these 13 loci, we experimentally define LOF variants in 23 patients (3.5%), aged 17 to 77 years, underlying autosomal recessive or dominant deficiencies. We show that human fibroblasts with mutations affecting this pathway are vulnerable to SARS-CoV-2. Inborn errors of TLR3- and IRF7-dependent type I IFN immunity can underlie life-threatening COVID-19 pneumonia in patients with no prior severe infection |
Science Mag |
Viral epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of severity (Science 29 Sep 2020) |
Revue scientifique américaine par l’Association américaine pour l’avancement des sciences (AAAS) |
Understanding humoral responses to SARS-CoV-2 is critical for improving diagnostics, therapeutics, and vaccines. Deep serological profiling of 232 COVID-19 patients and 190 pre-COVID-19 era controls using VirScan revealed over 800 epitopes in the SARS-CoV-2 proteome, including 10 epitopes likely recognized by neutralizing antibodies. Pre-existing antibodies in controls recognized SARS-CoV-2 ORF1, while only COVID-19 patients primarily recognized spike and nucleoprotein. A machine learning model trained on VirScan data predicted SARS-CoV-2 exposure history with 99% sensitivity and 98% specificity; a rapid Luminex-based diagnostic was developed from the most discriminatory SARS-CoV-2 peptides. Individuals with more severe COVID-19 exhibited stronger and broader SARS-CoV-2 responses, weaker antibody responses to prior infections, and higher incidence of CMV and HSV-1, possibly influenced by demographic covariates. Among hospitalized patients, males make greater SARS-CoV-2 antibody responses than females. |
Science Mag |
New test detects coronavirus in just 5 minutes (ScienceMag 08/10/2020) |
Revue scientifique américaine par l’Association américaine pour l’avancement des sciences (AAAS) |
Researchers have used CRISPR gene-editing technology to come up with a test that detects the pandemic coronavirus in just 5 minutes. The diagnostic doesn’t require expensive lab equipment to run and could potentially be deployed at doctor’s offices, schools, and office buildings. |
Science Mag |
A call for diagnostic tests to report viral load |
Revue scientifique américaine par l’Association américaine pour l’avancement des sciences (AAAS) |
Advocates point to new research indicating that CT values could help doctors flag patients at high risk for serious disease. Recent findings also suggest the numbers could help officials determine who is infectious and should therefore be isolated and have their contacts tracked down. CT value is an imperfect measure, advocates concede. But whether to add it to test results “is one of the most pressing questions out there,” says Michael Mina, a physician and epidemiologist at Harvard University’s T.H. Chan School of Public Health. |
Science Mag |
In situ structural analysis of SARS-CoV-2 spike reveals flexibility mediated by three hinges |
Revue scientifique américaine par l’Association américaine pour l’avancement des sciences (AAAS) |
The spike protein (S) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is required for cell entry and is the primary focus for vaccine development. In this study, we combined cryo–electron tomography, subtomogram averaging, and molecular dynamics simulations to structurally analyze S in situ. Compared with the recombinant S, the viral S was more heavily glycosylated and occurred mostly in the closed prefusion conformation. We show that the stalk domain of S contains three hinges, giving the head unexpected orientational freedom. We propose that the hinges allow S to scan the host cell surface, shielded from antibodies by an extensive glycan coat. The structure of native S contributes to our understanding of SARS-CoV-2 infection and potentially to the development of safe vaccines |
Science Mag |
Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients |
Revue scientifique américaine par l’Association américaine pour l’avancement des sciences (AAAS) |
This study confirms that serum and saliva IgG antibodies to SARS-CoV-2 are maintained in the majority of COVID-19 patients for at least 3 months PSO. IgG responses in saliva may serve as a surrogate measure of systemic immunity to SARS-CoV-2 based on their correlation with serum IgG responses. |
Science Mag |
REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters |
Revue scientifique américaine par l’Association américaine pour l’avancement des sciences (AAAS) |
An urgent global quest for effective therapies to prevent and treat COVID-19 disease is ongoing. We previously described REGN-COV2, a cocktail of two potent neutralizing antibodies (REGN10987+REGN10933) targeting non-overlapping epitopes on the SARS-CoV-2 spike protein. In this report, we evaluate the in vivo efficacy of this antibody cocktail in both rhesus macaques, which may model mild disease, and golden hamsters, which may model more severe disease. We demonstrate that REGN-COV-2 can greatly reduce virus load in lower and upper airways and decrease virus induced pathological sequalae when administered prophylactically or therapeutically in rhesus macaques. Similarly, administration in hamsters limits weight loss and decreases lung titers and evidence of pneumonia in the lungs. Our results provide evidence of the therapeutic potential of this antibody cocktail. |
Springer |
The association of treatment with hydroxychloroquine and hospital mortality in COVID-19 patients |
online collection of scientific, technological and medical journals, books and reference works |
This study investigates the association between the treatment with hydroxychloroquine and mortality in patients admitted with COVID-19. Routinely recorded, clinical data, up to the 24th of April 2020, from the 2075 patients with COVID-19, admitted in 17 hospitals in Spain between the 1st of March and the 20th of April 2020 were used. The following variables were extracted for this study: age, gender, temperature, and saturation of oxygen on admission, treatment with hydroxychloroquine, azithromycin, heparin, steroids, tocilizumab, a combination of lopinavir with ritonavir, and oseltamivir, together with data on mortality. Multivariable logistic regression models were used to investigate the associations. At the time of collecting the data, 301 patients had died, 1449 had been discharged home from the hospitals, 240 were still admitted, and 85 had been transferred to hospitals not included in the study. Median follow-up time was 8 (IQR 5–12) days. Hydroxychloroquine had been used in 1857 patients. Hydroxychloroquine was associated with lower mortality when the model was adjusted for age and gender, with OR (95% CI): 0.44 (0.29–0.67). This association remained significant when saturation of oxygen < 90% and temperature > 37 °C were added to de model with OR 0.45 (0.30–0.68) p < 0.001, and also when all the other drugs, and time of admission, were included as covariates. The association between hydroxychloroquine and lower mortality observed in this study can be acknowledged by clinicians in hospitals and in the community. Randomized-controlled trials to assess the causal effects of hydroxychloroquine in different therapeutic regimes are required. |
The Lancet |
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30764-7/fulltext |
Revue scientifique médicale hebdomadaire britannique |
Genomic evidence for reinfection with SARS-CoV-2: a case study“These findings suggest that the patient was infected by SARS-CoV-2 on two separate occasions by a genetically distinct virus. Thus, previous exposure to SARS-CoV-2 might not guarantee total immunity in all cases. All individuals, whether previously diagnosed with COVID-19 or not, should take identical precautions to avoid infection with SARS-CoV-2. The implications of reinfections could be relevant for vaccine development and application.” |
The Lancet |
Low risk of SARS-CoV-2 transmission by fomites in real-life conditions (29/09/2020) |
Revue scientifique médicale hebdomadaire britannique |
Our findings suggest that environmental contamination leading to SARS-CoV-2 transmission is unlikely to occur in real-life conditions, provided that standard cleaning procedures and precautions are enforced. These data would support Goldman’s point that the chance of transmission through inanimate surfaces is less frequent than hitherto recognised |
The Lancet |
False-positive COVID-19 results: hidden problems and costs (29/09/2020) |
Revue scientifique médicale hebdomadaire britannique |
To summarise, false-positive COVID-19 swab test results might be increasingly likely in the current epidemiological climate in the UK, with substantial consequences at the personal, health system, and societal levels (panel). Several measures might help to minimise false-positive results and mitigate possible consequences. Firstly, stricter standards should be imposed in laboratory testing. This includes the development and implementation of external quality assessment schemes and internal quality systems, such as automatic blinded replication of a small number of tests for performance monitoring to ensure false-positive and false-negative rates remain low, and to permit withdrawal of a malfunctioning test at the earliest possibility. Secondly, pretest probability assessments should be considered, and clear evidence-based guidelines on interpretation of test results developed. Thirdly, policies regarding the testing and prevention of virus transmission in health-care workers might need adjustments, with an immediate second test implemented for any health-care worker testing positive. Finally, research is urgently required into the clinical and epidemiological significance of prolonged virus shedding and the role of people recovering from COVID-19 in disease transmission. |
The Lancet |
Genomic evidence for reinfection with SARS-CoV-2: a case study |
Revue scientifique médicale hebdomadaire britannique |
These findings suggest that the patient was infected by SARS-CoV-2 on two separate occasions by a genetically distinct virus. Thus, previous exposure to SARS-CoV-2 might not guarantee total immunity in all cases. All individuals, whether previously diagnosed with COVID-19 or not, should take identical precautions to avoid infection with SARS-CoV-2. The implications of reinfections could be relevant for vaccine development and application. |
The Lancet |
COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study |
Revue scientifique médicale hebdomadaire britannique |
Patients with cancer with different tumour types have differing susceptibility to SARS-CoV-2 infection and COVID-19 phenotypes. We generated individualised risk tables for patients with cancer, considering age, sex, and tumour subtype. Our results could be useful to assist physicians in informed risk–benefit discussions to explain COVID-19 risk and enable an evidenced-based approach to national social isolation policies. |
The Lancet |
Beyond COVID-19—a paradigm shift in infection management? |
Revue scientifique médicale hebdomadaire britannique |
The more we realise how much SARS-CoV-2 has changed the world, the more we question the suitability of our prevention, management, and drug development strategies with respect to other major pathogens |